Skip to main content

Diabetes medications

Browse the latest news, expert commentary, and educational content on diabetes medications.

SGLT2 inhibitor use in type 2 diabetes management

Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.

  • » A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
  • » SGLT2 inhibitors: Key evidence and implications for clinical practice
  • » Translating SGLT2 inhibitor cardiovascular evidence into practice
  • » This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.

05-07-2021 | Glucagon | News

Dasiglucagon promising for severe hypoglycemia in children with type 1 diabetes

Dasiglucagon, a next-generation glucagon analog in a ready-to-use formulation, rapidly restores plasma glucose levels following severe hypoglycemia in children and adolescents with type 1 diabetes, show findings from a phase 3 trial.

05-05-2021 | Liraglutide (obesity) | News

Liraglutide beneficial for post-diet weight loss maintenance

A randomized trial supports giving people with obesity liraglutide to maintain weight loss after an 8-week diet, particularly if it is combined with regular vigorous exercise.

05-05-2021 | Dapagliflozin | News

Dapagliflozin gains FDA approval for CKD indication

Click through to read more on this announcement

05-05-2021 | Older adults | News

Overly tight glucose control in older adults linked to country income

Older people with type 2 diabetes are more likely to receive inappropriately intensive glucose-lowering treatment if they live in high- versus middle income countries, show data from the global DISCOVER study.

05-04-2021 | Medications | News

Objective assessment of medication taking advised to reduce type 2 diabetes complications

Suboptimal medication-taking identified through urine testing is associated with a higher prevalence of microvascular and macrovascular complications in people with type 2 diabetes than found with consistent usage, report researchers.

05-04-2021 | Obesity | News

Cagrilintide, semaglutide combination warrants further investigation for weight loss

Phase 1 trial results published in The Lancet suggest that combination treatment with the long-acting amylin analog cagrilintide plus high-dose semaglutide is well tolerated and may be a feasible treatment option for obesity.

04-30-2021 | SGLT2 inhibitors | News

Inequities in access to SGLT2 inhibitor therapy uncovered

Results from a US retrospective study suggest that usage rates of SGLT2 inhibitors remain low in people with type 2 diabetes, particularly among Black and Asian individuals, women, and lower-income groups.

04-23-2021 | Insulin | News

Pragmatic trial challenges ‘dogma’ of basal–bolus insulin for advanced type 2 diabetes

Combining a GLP-1 receptor agonist or SGLT2 inhibitor with basal insulin allows people with type 2 diabetes on a basal–bolus regimen to drop the prandial insulin, shows the pragmatic BEYOND trial.

04-22-2021 | Sulfonylureas | News

Real-world DISCOVER program highlights sulfonylurea drawbacks

Combining metformin with a sulfonylurea produces poorer non-glycemic outcomes than combining it with other second-line agents, show results from the global DISCOVER program.

04-21-2021 | Metformin | News

Metformin may reduce pneumonia risk

Researchers have found that people taking metformin for type 2 diabetes are less likely to be hospitalized or die due to pneumonia than those taking other glucose-lowering medications.

04-13-2021 | Dapagliflozin | News

DAPA-HF: Consistent benefits of dapagliflozin in men and women

Adding dapagliflozin to standard care improves outcomes for people with heart failure and reduced ejection fraction irrespective of sex, suggests a prespecified subgroup analysis of the DAPA-HF trial.

04-12-2021 | Dapagliflozin | News

Changes in vasoactive mediators may contribute to dapagliflozin benefits

Findings from a US randomized controlled trial suggest that add-on treatment with the SGLT2 inhibitor dapagliflozin reduces levels of some vasoconstrictors and increases some vasodilators in people with type 2 diabetes.

04-09-2021 | Pathophysiology | News

Ethnicity may be independently linked to beta-cell function

Black West African men have lower levels of insulin secretion in response to a meal than their White Northern European counterparts, irrespective of insulin sensitivity, study findings indicate.

04-08-2021 | Stroke | News

Genetic analysis backs causal link between blood glucose and stroke

A Mendelian analysis supports a causal effect of hyperglycemia on stroke risk, and the researchers also pinpoint the medications most likely to reduce this risk.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits